Skip to content

Three Chinese Omicron-Targeting Shots to Trial in Hong Kong

Updated on

Three Chinese inactivated vaccines that target the omicron variant of coronavirus have won approval to start clinical trials in Hong Kong, according to developers of the shots.

China National Biotec Group Company Ltd., a vaccine-developing subsidiary of state-owned China National Pharmaceutical Group Co. also known as Sinopharm, announced the news on its WeChat account on Saturday. The trials will look at the safety of the inoculations and their ability to stimulate an immune response in adults who have received two or three doses.